Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (V.S.S., K.K.K.); Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., V.J.L.); Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota (X.T., K.J.T., K.R.K.); and Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (L.L.).
Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (V.S.S., K.K.K.); Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., V.J.L.); Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota (X.T., K.J.T., K.R.K.); and Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (L.L.)
J Pharmacol Exp Ther. 2024 Nov 19;391(3):430-440. doi: 10.1124/jpet.124.002280.
Amyloid (A) deposition and neurofibrillary tangles are widely considered the primary pathological hallmarks of familial and sporadic forms of Alzheimer disease (AD). However, cerebrovascular inflammation, which is prevalent in 70% of AD patients, is emerging as another core feature of AD pathology. In our current work, we investigated the hypothesis that A42 exposure drives an increase in vascular cell adhesion molecule-1 (VCAM-1) expression, a cerebrovascular inflammatory marker expressed on the blood-brain barrier (BBB) endothelium in humans and murine models. We have demonstrated that the inflammation signaling pathway is upregulated in AD patient brains, and VCAM-1 expression is increased in AD patients compared with healthy controls. Furthermore, dynamic SPEC/CT imaging in APP,PS1 transgenic mice (a mouse model that overexpresses A42) demonstrated VCAM-1 upregulation at the BBB. Although there is a strong association between A42 exposure and an increase in VCAM-1 expression, the underlying mechanisms remain partially understood. Molecular mechanisms driving VCAM-1 expression at the BBB were investigated in polarized human cerebral microvascular endothelial cell monolayers. Moreover, by employing reverse-phase protein array assays and immunocytochemistry we demonstrated that A42 increases VCAM-1 expression via the Src/p38/MEK signaling pathway. Therefore, targeting the Src/p38/MEK pathway may help modulate VCAM-1 expression at the BBB and help mitigate cerebrovascular inflammation in Alzheimer disease. SIGNIFICANCE STATEMENT: Although considered a core pathological feature of Alzheimer disease, molecular pathways leading to cerebrovascular inflammation remain only partially understood. Moreover, clinical diagnostic methods for detecting cerebrovascular inflammation are underdeveloped. This study demonstrated the detection of VCAM-1 using radio-iodinated VCAM-1 antibody and single-photon emission computed tomography/computed tomography imaging. Additionally, exposure to A42 increases VCAM-1 expression on the blood-brain barrier endothelium via the Src/p38/MEK pathway. These findings are expected to aid in the development of diagnostic and therapeutic approaches for addressing cerebrovascular inflammation in AD.
淀粉样蛋白(A)沉积和神经原纤维缠结被广泛认为是家族性和散发性阿尔茨海默病(AD)的主要病理标志物。然而,在 70%的 AD 患者中普遍存在的脑血管炎症,正在成为 AD 病理学的另一个核心特征。在我们目前的工作中,我们假设 A42 暴露会导致血管细胞黏附分子-1(VCAM-1)表达增加,这是人类和小鼠模型中血脑屏障(BBB)内皮细胞上的一种脑血管炎症标志物。我们已经证明,AD 患者大脑中的炎症信号通路被上调,并且 AD 患者的 VCAM-1 表达增加。此外,APP、PS1 转基因小鼠(一种过度表达 A42 的小鼠模型)的动态 SPEC/CT 成像显示 BBB 上 VCAM-1 的表达上调。虽然 A42 暴露与 VCAM-1 表达增加之间存在很强的关联,但潜在的机制仍部分未知。我们在极化的人脑血管内皮细胞单层中研究了驱动 BBB 上 VCAM-1 表达的分子机制。此外,通过采用反相蛋白阵列测定和免疫细胞化学,我们证明 A42 通过Src/p38/MEK 信号通路增加 VCAM-1 的表达。因此,靶向 Src/p38/MEK 通路可能有助于调节 BBB 上的 VCAM-1 表达,并有助于减轻阿尔茨海默病中的脑血管炎症。意义声明:尽管被认为是阿尔茨海默病的核心病理特征,但导致脑血管炎症的分子途径仍部分未知。此外,用于检测脑血管炎症的临床诊断方法尚未开发。本研究使用放射性碘标记的 VCAM-1 抗体和单光子发射计算机断层扫描/计算机断层扫描成像来检测 VCAM-1。此外,A42 暴露通过 Src/p38/MEK 通路增加 BBB 内皮细胞上的 VCAM-1 表达。这些发现有望有助于开发针对 AD 中脑血管炎症的诊断和治疗方法。